Explains how Cloudbyz helps sponsors meet R3 service‑provider delegation expectations with AI‑assisted oversight when CROs and vendors hold large parts of the eTMF.
Sponsors can delegate TMF tasks, but not accountability for record integrity. Here is why episodic, single-system oversight no longer holds up, and what a native CTMS-to-eTMF backbone changes for biotech sponsors and mid-size CROs.
Service-provider delegation under ICH E6(R3) is where many biotech sponsors quietly feel most exposed. Operationally, you are already there. CROs and specialized vendors manage startup, monitoring, document workflows, and often large segments of the electronic trial master file. They operate their own systems, with their own audit models and KPIs. Your teams sign off on oversight plans, review responsibility matrices, and agree TMF expectations in contracts.
Regulatorily, the room for comfort has narrowed. E6(R3) reinforces a long-standing reality: sponsors may delegate tasks, but they cannot delegate accountability. They remain responsible for trial conduct and record integrity, regardless of where those records reside or who operates the primary system.
Appendix C defines essential records as the documents, metadata, and data that support ongoing management and reconstruction of trial conduct, and it acknowledges that some of those records will justifiably live outside the sponsor's TMF. Section C.2 expects them to be identifiable, version-controlled, and readily available. For portfolios that run heavily through CROs and vendors, that poses an awkward question: how do you prove, not just assert, that you had effective oversight of records and TMF behavior when key systems sit outside your direct control?
The EU Clinical Trials Regulation (EU CTR, Regulation 536/2014), now fully in force across the EU and EEA via CTIS, raises the bar further by making regulatory documentation more visible and more tightly timed. EMA's GCP Inspectors Working Group continues to highlight TMF-related weaknesses, including missing essentials, late filing, metadata and version-control gaps, and audit-trail issues, as recurring inspection themes. Against this spine, "the CRO has the TMF" is no longer an answer you can rely on.
The real challenge is that your oversight tools were built for a different era. They assume periodic reviews, spot checks, and static KPIs are enough. In a world where essential records span CTIS, CTMS, sponsor eTMFs, CRO eTMFs, and local repositories, that model is simply too slow. What you need is a way to see and manage TMF behavior in the context of CTMS reality, even when partners hold large parts of the underlying infrastructure. That is where a native CTMS-to-eTMF platform with agentic AI has leverage.
The weakness in most oversight models is not intent. It is instrumentation. On paper, the governance looks solid. Responsibility matrices define who does what. TMF ownership is spelled out in contracts. Oversight plans commit to periodic reviews, KPIs, and escalation thresholds. Sponsors review SOPs, attend governance meetings, and sample artifacts.
In practice, three structural problems keep surfacing when regulators or internal QA dig beneath the surface.
1. Oversight is episodic rather than continuous. Sponsors often rely on quarterly TMF reviews, milestone-based QC snapshots, or pre-inspection health checks. That is hard to square with a guidance spine that expects ongoing, risk-proportionate review of data, metadata, and audit trails.
2. Signals arrive without CTMS context. CRO-operated eTMFs may provide completeness metrics, late-filing KPIs, or QC dashboards, but often in isolation from the sponsor's CTMS, where study, country, and site timelines actually live. Without CTMS context, sponsors see symptoms such as late filing and metadata errors, but not how those symptoms align, or fail to align, with submissions, SIVs, protocol amendments, and lock decisions.
3. Multi-repository reality is invisible. Under Appendix C, essential records include SOPs, validation records, MSAs, and other items that may justifiably live outside a classical TMF. EU CTR and CTIS add another layer of distributed evidence. Yet most oversight plans still act as if "the TMF" is a single system. The result is that cross-repository behavior, meaning how CTIS, CRO eTMFs, and sponsor systems together tell the story of trial conduct, remains largely unmeasured.
That is why, when problems surface, sponsors so often fall back to manual reconstruction. They pull exports from CRO eTMFs, CTMS, CTIS where relevant, and internal repositories, then stitch together a picture of what actually happened. It is oversight, but only in hindsight.
E6(R3) narrows the room for that approach. The guideline's principles make explicit that sponsors remain responsible for trial conduct and record integrity even when service providers operate the systems. Appendix C treats essential records as a fabric across repositories, not as a folder tree in a single application. Section 4.2.3 expects audit-trail and metadata review to be planned and risk-based, not just an emergency measure.
Under post-2024 funding pressure and EU CTR timelines, sponsors do not have the luxury of rebuilding that view from scratch each time. They need an operating layer that can see CTMS reality, TMF behavior, and partner performance together, and they need it without having to re-platform every CRO.
Cloudbyz is designed to be that operating layer for sponsors, without forcing a single-vendor world. As the only 100% Salesforce-native unified eClinical platform, Cloudbyz is a unifier that breaks data silos across clinical operations rather than a point solution. Its native CTMS-to-eTMF connection on Salesforce gives sponsors a governed backbone where study, country, and site records, operational milestones, and TMF artifacts share the same data and audit model.
On that backbone, the AI eTMF Agent is Cloudbyz's confirmed agentic AI capability for eTMF. It acts inside the eTMF workflow to:
Sponsors can use that spine whether CROs file directly into Cloudbyz eTMF or whether key segments are integrated from partner systems. The goal is not to centralize every file. It is to centralize oversight.
Because CTMS and eTMF live on the same Salesforce-native platform, sponsor teams can see CRO behavior in context and ask questions that static dashboards cannot answer:
This is where the AI eTMF Agent does real work for Regulatory, Clinical Operations, and Quality leads. It handles the routine cleaning that used to consume oversight bandwidth, leaving people free to focus on the exceptions, the patterns that matter under Section 4.2.3 and Appendix C.
For EU portfolios, EMA's Step 5 adoption of E6(R3), with a 23 July 2025 effective date, alongside EU CTR and CTIS, sets the context for this approach. For US portfolios, 21 CFR Part 11 remains the anchor for electronic records and signatures, with ALCOA+ as the working rubric. Cloudbyz's Salesforce-native audit model supports both, without needing separate audit stories for CRO data and sponsor data.
For biotech sponsors and mid-size CROs, the practical benefit is sponsor oversight you can evidence rather than assert:
See what sponsor oversight looks like when your electronic trial master file and native CTMS share one Salesforce-native backbone, and an AI eTMF Agent handles the routine reconciliation work every day, instead of a tiger team doing it once a year.